Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02EOH
|
|||
| Former ID |
DIB010591
|
|||
| Drug Name |
SGT-53
|
|||
| Synonyms |
P53 gene stimulator (solid tumor), Synergene Therapeutics
Click to Show/Hide
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Pancreatic cancer [ICD-11: 2C10; ICD-9: 185] | Phase 2 | [1] | |
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 2 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [3] | ||
| Company |
Synergene Therapeutics Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02340156) Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma. U.S. National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT00470613) Safety Study of Infusion of SGT-53 to Treat Solid Tumors. U.S. National Institutes of Health. | |||
| REF 4 | Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr;20(4):222-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.